Aragon Pharmaceuticals, Inc. clinical trials

Acquired by Johnson & Johnson, 2013 · source ↗

The registry lists 16 studies whose lead sponsor is Aragon Pharmaceuticals, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 28, 2026.

Studies

Recruiting first, then most recently updated. Showing 16 of 16. All Johnson & Johnson studies →

• A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT01946204Phase 3

  Sponsor listed in the registry: Aragon Pharmaceuticals, Inc. · Unclear whether first submitted before or after Aragon Pharmaceuticals, Inc. became part of Johnson & Johnson

• A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPCActive, not recruitingNCT02489318Phase 3

  Sponsor listed in the registry: Aragon Pharmaceuticals, Inc. · First submitted after Aragon Pharmaceuticals, Inc. became part of Johnson & Johnson

• An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)Active, not recruitingNCT02257736Phase 3

  Sponsor listed in the registry: Aragon Pharmaceuticals, Inc. · First submitted after Aragon Pharmaceuticals, Inc. became part of Johnson & Johnson

• A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT02123758Phase 1

  Sponsor listed in the registry: Aragon Pharmaceuticals, Inc. · First submitted after Aragon Pharmaceuticals, Inc. became part of Johnson & Johnson

• A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate CancerActive, not recruitingNCT02592317Phase 1

  Sponsor listed in the registry: Aragon Pharmaceuticals, Inc. · First submitted after Aragon Pharmaceuticals, Inc. became part of Johnson & Johnson

• An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLASActive, not recruitingNCT02531516Phase 3

  Sponsor listed in the registry: Aragon Pharmaceuticals, Inc. · First submitted after Aragon Pharmaceuticals, Inc. became part of Johnson & Johnson

• Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)CompletedNCT01171898Phase 1/2

  Sponsor listed in the registry: Aragon Pharmaceuticals, Inc. · First submitted before Aragon Pharmaceuticals, Inc. became part of Johnson & Johnson

• An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate CancerNo longer availableNCT03523338

  Sponsor listed in the registry: Aragon Pharmaceuticals, Inc. · First submitted after Aragon Pharmaceuticals, Inc. became part of Johnson & Johnson

• Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone AcetateCompletedNCT01792687Phase 1

  Sponsor listed in the registry: Aragon Pharmaceuticals, Inc. · Unclear whether first submitted before or after Aragon Pharmaceuticals, Inc. became part of Johnson & Johnson

• A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic FunctionCompletedNCT02524717Phase 1

  Sponsor listed in the registry: Aragon Pharmaceuticals, Inc. · First submitted after Aragon Pharmaceuticals, Inc. became part of Johnson & Johnson

• Bioavailability Study of 3 Tablet Formulations vs. Capsule Formulation of JNJ-56021927 in Fasting Healthy Male ParticipantsCompletedNCT02160756Phase 1

  Sponsor listed in the registry: Aragon Pharmaceuticals, Inc. · First submitted after Aragon Pharmaceuticals, Inc. became part of Johnson & Johnson

• A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc StudyCompletedNCT02578797Phase 1

  Sponsor listed in the registry: Aragon Pharmaceuticals, Inc. · First submitted after Aragon Pharmaceuticals, Inc. became part of Johnson & Johnson

• The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate CancerCompletedNCT01790126Phase 2

  Sponsor listed in the registry: Aragon Pharmaceuticals, Inc. · Unclear whether first submitted before or after Aragon Pharmaceuticals, Inc. became part of Johnson & Johnson

• A Study to Assess the Relative Bioavailability of 7 Test Tablet Formulations of JNJ-56021927 With Respect to the Capsule Formulation of JNJ-56021927 in Healthy Male ParticipantsCompletedNCT02031666Phase 1

  Sponsor listed in the registry: Aragon Pharmaceuticals, Inc. · First submitted after Aragon Pharmaceuticals, Inc. became part of Johnson & Johnson

• Study to Assess Drug-Drug Interaction Between Itraconazole or Gemfibrozil and JNJ-56021927CompletedNCT02230033Phase 1

  Sponsor listed in the registry: Aragon Pharmaceuticals, Inc. · First submitted after Aragon Pharmaceuticals, Inc. became part of Johnson & Johnson

• 14C-ARN-509 Microtracer Label AME and Absolute BA StudyCompletedNCT01822041Phase 1

  Sponsor listed in the registry: Aragon Pharmaceuticals, Inc. · Unclear whether first submitted before or after Aragon Pharmaceuticals, Inc. became part of Johnson & Johnson